The estimated 15-year risk of ipsilateral recurrence was 11.4% for patients treated with tamoxifen and 19% for patients who did not receive tamoxifen, a statistically significant difference.

Tamoxifen is an oral anti-estrogen used to treat women with estrogen receptor positive breast cancer. It is taken once daily and blocks the estrogen receptor on cancer and normal cells.

Background: Tamoxifen is standard adjuvant treatment for postmenopausal women with hormone-receptor-positive breast cancer. We assessed the benefit of adding chemotherapy to adjuvant tamoxifen and ...

Women taking a new breast cancer drug are living longer than those taking Tamoxifen - the current 'gold standard' treatment. Doctors predict the new drug, Arimidex, will improve long-term survival ...

Tamoxifen is an antiestrogen, prescribed for breast cancer. The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Abiraterone ...

Weekly administration of prophylactic tamoxifen is much less effective than the standard daily regimen in preventing the adverse breast effects induced by bicalutamide. Bicalutamide monotherapy is ...

Tamoxifen treatment has been linked to an excess risk of nonalcoholic steatohepatitis, which is characterized by inflammation and fatty deposits in the liver. Bruno and colleagues have ...

F or patients with "good-risk" ductal carcinoma in situ (DCIS) who underwent breast- conserving surgery and did not receive radiotherapy, tamoxifen significantly decreased the risk of recurrence ...

Switching to an AI following 2–3 years of initial adjuvant tamoxifen is an effective option for patients unable to begin treatment with an AI. This article evaluates the most up-to-date results ...

PREMIER LEAGUE stars are among NINE footballers to have been caught using banned substances since 2022. The number of players ...